Free Newsletter
Hospira finishes for Genzyme
Genzyme has tapped Hospira for fill and finish of Cerezyme and Fabrazyme, helping to alleviate shortages of two key drugs. The Boston-based big biotech is still struggling to get its Allston Landing plant up to full compliance following last summer's shutdown. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
